Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma
CD70 has emerged as a promising immunotherapeutic target in renal cell carcinoma (RCC), with both CD70-directed monoclonal antibodies and chimeric antigen receptor (CAR)-based therapies currently under development. Here, we describe a protocol for the generation of human CD70-directed allogeneic CAR-natural killer T (NKT) (<sup>Allo</sup>CAR70-NKT) cells derived from cord blood CD34<sup>+</sup> hematopoietic stem and progenitor cells (HSPCs) using a clinically guided culture. Furthermore, we describe the therapeutic efficacy of <sup>Allo</sup>CAR70-NKT cells in mediating cytotoxic activity against RCC cell lines in vitro. For complete details on the use and execution of this protocol, please refer to Li et al.<sup>1</sup>.
Authors
- Lihui Yang (ORCID: https://orcid.org/0000-0001-7594-4653)
- Yan-Ruide Li
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- STAR Protocols
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1016/j.xpro.2025.104340
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00